Man, Mosquito, Malaria Vaccine
The a16z Show2 Touko 2021

Man, Mosquito, Malaria Vaccine

Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.

So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- Rajeev Venkayya of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and what's left to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?

Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been nearly a century in the making.

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jaksot(1000)

Heroes & Myths in Entrepreneurship -- Guy Raz

Heroes & Myths in Entrepreneurship -- Guy Raz

"I'm in a movie, but it's the wrong movie."For better or for worse, we tell the story of entrepreneurs as one of the mythical hero's journey: that's there's a call, a test (multiple tests!), a destina...

12 Syys 202038min

The Question of Education

The Question of Education

Monopoly, oligopoly, cartel. All three of those words can describe the (not so) modern education system today, given the cost structures, economics, and accreditation capture -- in everything from who...

11 Syys 202058min

Pandemic Relief and Fraud: Willful Deceit or Design Defect?

Pandemic Relief and Fraud: Willful Deceit or Design Defect?

This episode examines the potential for misuse and fraud among those applying for the Paycheck Protection Program (PPP)—and how fintech and software provide overlooked tools to stop it.  On March 27th...

4 Syys 202040min

Measuring & Managing Community Orgs, Developer Relations and Beyond

Measuring & Managing Community Orgs, Developer Relations and Beyond

Okay, so we know community is important -- whether for developer relations for your product or other types of communities -- but how do we measure the success of community initiatives and even artifac...

30 Elo 202033min

Reining in Complexity: Data Science & Future of AI/ML Businesses

Reining in Complexity: Data Science & Future of AI/ML Businesses

There is no spoon. Or rather, “There is no such thing as ‘data’, there’s just frozen models”, argues Peter Wang, the co-founder and CEO of Anaconda — who also created the PyData conferences and grew t...

21 Elo 202044min

Online Learning and the Ed Tech Debate

Online Learning and the Ed Tech Debate

This episode is all about education and technology, a topic that’s especially top of mind this week as students in much of the country return to school—virtually. The intersection of learning and tech...

17 Elo 202048min

On Vaccines and Vaccinology, in COVID and Beyond

On Vaccines and Vaccinology, in COVID and Beyond

WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will...

14 Elo 202056min

Turning Open Source Developers Into Superfans

Turning Open Source Developers Into Superfans

In this episode, we continue our community series with a recent discussion that applies to many kinds of community building. Today’s topic: How do you create a platform that people not only use, but t...

10 Elo 202045min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
mimmit-sijoittaa
rss-rahapodi
psykopodiaa-podcast
hyva-paha-johtaminen
rss-rahamania
inderespodi
rss-lahtijat
rss-oivalluksia-rahasta-elamasta
ostan-asuntoja-podcast
rahapuhetta
oppimisen-psykologia
rss-bisnesta-bebeja
rss-sisalto-kuntoon
herrasmieshakkerit
leadcast
lakicast
rss-startup-ministerio
rss-rikasta-elamaa
rss-inderes